Posaconazole for prevention of invasive fungal infections：a rapid health technology assessment
- VernacularTitle:泊沙康唑预防侵袭性真菌感染的快速卫生技术评估
- Author:
Yujie LI
1
;
Jiantong MA
2
;
Gerile HUANG
3
;
Wenjing ZHANG
3
;
Hao GUO
3
Author Information
1. Dept. of Pharmacy，Inner Mongolia People’s Hospital，Hohhot 010017，China;School of Pharmacy，Baotou Medical College，Inner Mongolia Baotou 014040，China
2. School of Pharmacy，Baotou Medical College，Inner Mongolia Baotou 014040，China
3. Dept. of Pharmacy，Inner Mongolia People’s Hospital，Hohhot 010017，China
- Publication Type:Journal Article
- Keywords:
posaconazole;
invasive fungal infections;
prevention;
efficacy;
safety;
cost-effectiveness
- From:
China Pharmacy
2026;37(10):1364-1369
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety， and cost-effectiveness of posaconazole for the prevention of invasive fungal infections （IFIs）. METHODS PubMed， Embase， CNKI， Wanfang data and other Chinese and English databases were searched， as well as the official websites of related health technology assessment （HTA）. Systematic review （SR）/meta-analysis， pharmacoeconomic studies， and HTA reports of posaconazole for the prevention of IFIs were collected. The retrieval time limit was from the establishment of the database to November 1， 2025. After screening the literature， extracting the data， and evaluating the quality of the literature， the results of the included studies were descriptively analyzed. RESULTS A total of 45 studies were included， involving 17 SR/meta-analyses， 26 pharmacoeconomic studies， 1 SR/meta-analysis combined with a pharmacoeconomic study， and 1 HTA report. In terms of effectiveness， posaconazole was significantly superior to other antifungal drugs （eg.， fluconazole， itraconazole） in reducing the incidence of IFIs， the incidence of invasive aspergillosis， all-cause mortality， and IFI-related mortality （ P ＜0.05）. In terms of safety， posaconazole was significantly superior to other antifungal drugs in the incidence of total adverse reactions （ P ＜0.05）， but there was no significant difference in the incidence of serious adverse reactions， the incidence of gastrointestinal advers e reactions， drug-induced liver injury， and the withdrawal rate due to adverse drug reactions （ P ＞0.05）. In terms of cost-effectiveness， most studies have shown that posaconazole possesses more cost-effectiveness advantages. CONCLUSIONS Posaconazole demonstrates favorable efficacy， safety， and cost-effectiveness in preventing IFIs.
